Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC for $8 million on August 31, 2023. Transaction is subject to Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. and Morris, Nichols, Arsht & Tunnell LLP served as legal advisors to EPI Health, LLC and K&L Gates LLP served as legal advisor to Mayne Pharma Group Limited (ASX:MYX).